Literature DB >> 7517365

Determination of amino acids on agretopes of pigeon cytochrome c-related peptides specifically bound to I-A allelic products.

Y Itoh1, K Ogasawara, K Takami, T Gotohda, H Naruse, R A Good, K Onoé.   

Abstract

In our prior study it was demonstrated that residues 46 and 54 on a synthetic peptide, AEGFSYTVANKNKGIT (50V), work as an agretope (site contacts with major histocompatibility complex molecules) and residues 50 and 52 function as an epitope (site contacts with T cell receptor), when tri-molecular complexes are formed among 50V,I-Ab and the T cell receptor. 50V was composed of residues 43 to 58 of pigeon cytochrome c (p43-58) except that the aspartic acid (D) at residue 50 was substituted by valine (V). Substitution of agretopic residues on 50V changed this I-Ab-binding peptide to an I-Ak-binding peptide, suggesting that positions 46 and 54 work as an agretope in I-Ak-restricted T cell responses. In the present study we examined whether residues 46 and 54 of 50V worked as agretopes in T cell responses restricted to other I-A haplotypes. The 50V-related peptides with phenylalanine (F) at position 46 and alanine (A) at position 54 bound tightly to I-Ab, I-Ad, I-Aq and I-As molecules and stimulated T cells most potently in mice bearing these I-A haplotypes. In contrast, 50V-related peptides carrying D at position 46 and A at position 54 bound most potently to I-Ak molecules, and the peptides with arginine (R) at position 46 and A at position 54 bound most efficiently to I-Av molecules. The present findings, thus, demonstrate that the agretopic positions on the p43-58 related peptides are preserved in T cell responses restricted to each I-A haplotype studied, and that the specific amino acids on the agretopic positions exist a priori for each I-A allele-specific structure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517365     DOI: 10.1002/eji.1830240113

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Interaction of pigeon cytochrome c-(43-58) peptide analogs with either T cell antigen receptor or I-Ab molecule.

Authors:  Y Itoh; K Kajino; K Ogasawara; A Takahashi; K Namba; I Negishi; N Matsuki; K Iwabuchi; M Kakinuma; R A Good; K Onoé
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

2.  Identification of amino acid residues of the T-cell epitope of Mycobacterium tuberculosis alpha antigen critical for Vbeta11(+) Th1 cells.

Authors:  A Kariyone; K Higuchi; S Yamamoto; A Nagasaka-Kametaka; M Harada; A Takahashi; N Harada; K Ogasawara; K Takatsu
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cells.

Authors:  Brenda Faiola; Carolyn Doyle; Eli Gilboa; Smita Nair
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

4.  Role of natural killer cells in resistance against friend retrovirus-induced leukemia.

Authors:  N Iwanami; A Niwa; Y Yasutomi; N Tabata; M Miyazawa
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Identification of a peptide inducing experimental autoimmune uveoretinitis (EAU) in H-2Ak-carrying mice.

Authors:  K Namba; K Ogasawara; N Kitaichi; N Matsuki; A Takahashi; Y Sasamoto; S Kotake; H Matsuda; K Iwabuchi; S Ohno; K Onoé
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

6.  Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.

Authors:  Koji Teramoto; Yasuhiko Ohshio; Takuya Fujita; Jun Hanaoka; Keiichi Kontani
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-15       Impact factor: 4.553

7.  Identification of Streptococcus mutans PAc peptide motif binding with human MHC class II molecules (DRB1*0802, *1101, *1401 and *1405).

Authors:  H Senpuku; K Yanagi; T Nisizawa
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.